A Phase Ib/II.a Clinical Study of the Safety, Pharmacokinetics and Preliminary Efficacy of MG-K10Humanized Monoclonal Antibody Injection in Adolescent Patients with Moderate to Severe Atopic Dermatitis Aged 12-18 Years.
Latest Information Update: 17 Jan 2025
At a glance
- Drugs Comekibart (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Shanghai Mabgeek Biotech
Most Recent Events
- 17 Jan 2025 New trial record